ALNY optimism on AMVUTTRA growth, reduced competition and pipeline progress
TradingView News cites strong AMVUTTRA cardiomyopathy launch-driven revenue and first-line market growth. It also points to extended tafamidis exclusivity, a failed rival trial, international expansion, and pipeline progress.